Background-It is unclear if the presence of atrial fibrillation (AF) on admission is associated with worse in-hospital outcomes in patients hospitalized with heart failure (HF). This study evaluated the clinical characteristics, management, length of stay, and mortality of HF patients with and without AF. Methods and Results-We studied 99 810 patients from 255 sites admitted with HF enrolled in Get With The Guidelines-Heart Failure between January 1, 2005, and December 31, 2010. Patients with AF on admission were compared with patients in sinus rhythm. A total of 31 355 (31.4%) HF patients presented with AF, of which 6701 (21.3%) were newly diagnosed. Patients in AF were older (77Ϯ12 versus 70Ϯ15, PϽ0.001) and were more likely to have history of stroke and valvular heart disease. AF patients had higher B-type natriuretic peptide levels and ejection fraction (42Ϯ17% versus 39Ϯ17%, PϽ0.001). AF patients were more likely to be hospitalized Ͼ4 days (48.8% versus 41.5%, PϽ0.001), discharged to a facility other than home (28.5% versus 19.7%, PϽ0.001), and had higher hospital mortality rate (4.0% versus 2.6%, PϽ0.001). AF, particularly newly diagnosed, was independently associated with adverse outcomes (adjusted odds ratios and 95% confidence intervals for mortality 1.17, 1.05-1.29, Pϭ0.0029, and 1.29, 1.10 -1.52, Pϭ0.0023 for AF and newly diagnosed AF, respectively). Conclusions-In patients hospitalized with HF, AF is present in one-third and is independently associated with adverse hospital outcomes and longer length of stay. Whether prompt restoration of sinus rhythm would improve outcomes in patients hospitalized with HF and new-onset or paroxysmal AF is unclear and requires further study. (Circ Heart Fail. 2012;5:191-201.)
AF. We hypothesize that the detrimental hemodynamic effects of AF, especially in patients with new-onset AF, may lead to or worsen in-hospital outcomes for these patients.
Methods

Data Collection
The Get With The Guidelines-Heart Failure (GWTG-HF) program is among the largest quality improvement initiatives focusing on patients hospitalized with HF, the design of which has been previously described. 17, 18 Hospitals participating in the registry use a web-based patient management tool (PMT, Outcomes Sciences Inc, Cambridge, MA) to collect data for consecutive patients admitted with HF to receive recommendations for qualitative improvement in medical management. Patients hospitalized with new or worsening HF as primary diagnosis or patients that developed significant HF symptoms such that HF was the primary discharge diagnosis were included. Patients were enrolled into the program regardless of their left ventricular function. Hospitals from all regions of the United States are represented and a variety of institutions participate, from community hospitals to large tertiary medical centers. Data collected for each HF patient include demographics, medical/surgical history including any history of AF, admission medications, physical examination, rhythm at time of admission, serum laboratory tests, pharmacological and nonpharmacologic interventions, in-hospital outcomes, and discharge information. Trained hospital personnel enter the data by using standardized definitions. All participating hospitals were required to submit the GWTG protocol to their institutional review board for approval. Because data collected were used for qualitative hospital improvement, sites were granted a waiver of informed consent under the common rule. Outcome Sciences Inc serves as the data collection and the Duke Clinical Research Institute (Durham, NC) serves as the data analysis center.
Study Population
The study evaluated patients enrolled in the GWTG-HF registry between January 2005 and January 2011. A total of 136 465 patients from 282 participating hospitals were registered during that period. From this group, patients were excluded due to missing discharge status (nϭ4320) or missing initial heart rhythm and/or history of AF (nϭ32 335). The final study population consisted of 99 810 patients from 255 sites (Figure 1 ).
Definitions
Several patient populations were classified according to the temporal characteristics history of their AF and their respective rhythm findings on admission ECG. Current AF was defined as the presence of AF on admission irrespective of history of AF. Patients in preexisting AF were in AF on admission and had a reported medical history of AF. New onset was defined as presence of AF on admission with negative medical history of AF. Patients in the category "sinus rhythm" were in sinus rhythm on presentation irrespective of history of AF.
Outcome Measures
The primary outcome measure of interest was in-hospital mortality. Additional outcomes of interest included length of hospital stay and discharge location (home versus other). Quality of care was assessed using the GWTG-HF performance and quality measures as previously described. 17, 18 
Statistical Analysis
Categorical variables were summarized using percentages and compared using Cochran Mantel Haenzel general association statistic test; continuous variables were presented using means and standard deviation and compared using Wilcoxon rank sum test. Patients with AF were compared with those in sinus rhythm. Subgroups of patients with preexisting AF and new-onset AF were also compared. The multivariable association between presence of AF and primary end points was assessed using a logistic regression model with the generalized estimating equations method to account for withinhospital clustering and obtaining unadjusted and adjusted odds ratios and confidence intervals. For adjusted models, the following variables were included: age (per 10 years), race, sex, chronic obstructive pulmonary disease, stroke/transient ischemic attack, depression, diabetes mellitus, renal failure, dyslipidemia, hypertension, peripheral artery disease, smoking, ischemic etiology, valvular heart disease, heart rate, blood pressure, ejection fraction, sodium level, hemoglobin, serum creatinine, serum blood urine nitrogen, hospital region where patient is admitted, hospital academic status, and hospital heart transplant capability. To evaluate the importance of ejection fraction (EF Ն40% versus Ͻ40%) on outcomes, we include an interaction term in the overall model and compute the odds ratios for AF based on the above 2 subgroups. We also provide the probability value for the interaction or p for heterogeneity. All analyses were performed using SAS software (version 9.1, SAS Institute, Cary, NC). Probability values were 2-sided, with PϽ0.01 considered statistically significant to adjust for multiple comparisons among our 3 groups. All authors had access to data and assume responsibility of the accuracy of the analysis.
Results
Of the 99 810 patients from 255 hospital sites in the final analysis, 31 355 (31.4%) patients presented in AF, of which 6701 (6.7%) were newly diagnosed ( Figure 1 ). AF was more prevalent in patients with history of HF compared with patients with newly diagnosed HF (32.78% versus 28.82%, PϽ0.001), whereas newly diagnosed AF was more prevalent in patients with newly diagnosed HF (9.09% versus 5.27%, PϽ0.001) (online-only Data Supplement Table I ). Baseline characteristics of the study population are shown in Table 1 . Patients in AF were older (77Ϯ12 versus 70Ϯ15 years, PϽ0.001) and had similar gender distribution with patients in sinus rhythm. Comorbidities that were more frequent in patients with AF included history of stroke, valvular heart disease, HF, and pulmonary disease. Diabetes mellitus was highly prevalent in both groups, but moderately less frequent in AF patients. On presentation, patients in AF had higher heart rates and lower blood pressure. Laboratory tests on admission in patients with AF were significant for lower serum creatinine and blood urea nitrogen, higher frequency of abnormal troponin levels and higher serum B-type natriuretic peptide (BNP) levels. Echocardiogram performed during admission showed a higher EF in AF patients.
Subgroup analysis showed that patients with newly diagnosed AF had different clinical profiles from patients in sinus rhythm or preexisting AF. Although older than patients in sinus rhythm, patients with newly diagnosed AF were younger than patients with preexisting AF. The prevalence of comorbid diagnoses was significantly less than the other 2 groups except for diabetes and need for dialysis (Table 1) . Notably, patients with new-onset AF had less frequent HF history compared with the 2 other study groups. At presentation, these patients had heart rates that were higher than both patients in sinus rhythm and preexisting AF, whereas systolic blood pressure was slightly higher than in patients with preexisting AF. Last, EF was higher than patients with sinus rhythm and clinically comparable with EF in patients with preexisting AF (Table 1) .
Differences in medical therapy before hospital admission in patients in sinus rhythm and AF were also noted (onlineonly Data Supplement Table II ). Patients in AF were less likely to be receiving therapy with angiotensin-converting enzyme inhibitors (ACEi), aspirin, hydralazine, statins, and nitrates and were more likely to be on treatment with antiarrhythmics, digoxin, calcium channel blockers, diuretics, and warfarin. Medication treatment rates before hospitalization for patients with preexisting diagnosis of HF and reduced EF are shown in online-only Data Supplement Table III . In these patients, treatment rates with ACEi/ARB and ␤-blockers were above 60% and patients in SR were more likely to be treated compared with AF patients. Significant differences among the populations stratified by AF status were also identified with respect to hospital management ( Table 2 ). Patients in AF underwent less invasive procedures in general, including lower frequency of right cardiac catheterization, stress testing, and coronary angiography. Multivariable analysis showed that presence of AF was independently associated with less cardiac catheterization after adjusting for age, medical history, laboratories, vitals, and hospital characteristics (online-only Data Supplement Table  IV ). As expected, cardioversion was significantly more prevalent in the AF group. Renal replacement therapy during hospitalization was more common for the sinus rhythm group.
In regard to conformity with HF performance and quality measures during hospitalization and on discharge, small differences were identified between the 2 patient groups. Patients in AF were discharged with all-or-none composite measure rate of 86.8%. Rates of conformity with each performance and quality measure are shown in (Table 3) . Patients in AF were less commonly discharged on ACEi or ARB, evidenced-based ␤-blocker and lipid-lowering agent and received less frequently prophylaxis for deep venous thrombosis during hospitalization.
Hospital outcomes were significantly different among the patient groups by the presence or absence of AF (Table 4 ). Hospital length of stay was significantly longer in patients in AF (mean, 5 versus 4 days; PϽ0.001, in patients with AF and sinus rhythm, respectively), and patients in AF were more likely to be discharged to a facility other than home (28.5% versus 19.7%, PϽ0.001). Hospital mortality rate was significantly higher in the AF group (4.0% versus 2.6%, PϽ0.001). Among patients in AF, those with newly diagnosed AF had even lengthier hospitalization and higher hospital mortality than both patients in sinus rhythm and preexisting AF ( Table 4 and Figure 2 ). In multivariable analysis, the presence of AF was independently associated with adverse in-hospital outcomes including length of stay more than 4 days, discharge to a facility other than home, and hospital mortality ( Table 4 ). Notably, newly diagnosed AF had a stronger independent association with adverse outcome ( Table 4 ).
The relationships between AF and outcomes were also examined separately in patients with reduced and preserved EF HF patients. The associations between AF and outcomes in the adjusted analyses were similar for both EF subgroups (EF Ն40% and Ͻ40%), suggesting that the relationship between AF and outcomes applies irrespective of type of HF (preserved versus reduced EF HF) ( Table 5 ).
Discussion
In this large, multicenter, national HF registry of patients admitted with HF, 31.4% of patients presented in AF, and, of those in AF, 21.3% were newly diagnosed. Patients in AF were older and more likely to have a history of stroke and valvular heart disease. AF patients underwent fewer invasive procedures including right and left heart catheterization. AF patients were more likely to be hospitalized Ͼ4 days, discharged to a facility other than home, and had higher hospital mortality rates. AF, particularly newly diagnosed, was independently associated with adverse in-hospital outcomes among patients hospitalized with HF, including mortality. The present study demonstrates the very high prevalence of AF among patients hospitalized with HF patients and expands on current knowledge regarding the potential contributions of AF to adverse clinical outcomes among patients hospitalized with HF.
The prevalence of AF in this patient population is remarkably high. This incidence is higher than most prior case series with ambulatory patients with HF that have reported an incidence of AF between 13-27%. 7,8,11,19 -21 This difference could be attributed to the fact that our series captures patients in a state of decompensated HF requiring admission. Therefore, adverse hemodynamics of increased left atrial pressure, enhanced cathecholaminergic state, hypoxemia, and tachycardia may have promoted the development of AF. In agreement with our finding in a much smaller cohort of 4596 patients admitted to the Mayo Clinic with HF, 34.9% were in AF. 19 A main difference in baseline characteristics of the 2 groups is that patients in AF were older. Development of AF has been previously associated with age in the Framingham study, which showed a 1 in 4 lifetime risk of developing AF in adults over the age of 40. 22 Conditions that are classically associated with development or presence of AF, namely, Actual numbers are presented on first row of each categorical variable and percentages on the second. For continues variables, means and standard deviations are presented with the number of patients for each subgroup in parenthesis.
AF indicates atrial fibrillation; BMI, body mass index; JVP, jugular venous pressure; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous intervention; CABG, coronary artery bypass graft; HF, heart failure; CVA, cerebrovascular accident; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary disease; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen.
*Median values for variables that did not follow normal distribution. †P comparison between sinus rhythm, preexisting AF, and new-onset AF. ‡P comparison between preexisting and new-onset AF. §Statistically significant differences. valvular disease and chronic obstructive pulmonary disease and stroke were, as expected, more prevalent in the AF group. Subgroup analysis showed differences in clinical characteristics in patients with newly diagnosed AF. It appears that those patients have fewer comorbidities than patients in preexisting AF or sinus rhythm, which is in agreement with prior reports. 15 Specifically, almost half of patients who were diagnosed with AF for the first time were simultaneously diagnosed with HF. This is in contrast to patients with preexisting AF, where only a quarter of patients with preexisting AF were de novo diagnosed with HF. This observation brings the interesting notion of new onset AF being the initiating mechanism of HF decompensation. The deleterious effects of both increased heart rate and irregularity in combination with loss of atrial kick could result in adverse hemodynamic consequences, namely, decrease in ventricular filling time, increase in oxygen consumption, and ultimately reduction in cardiac output. 23 The effects of onset of AF in patients with chronic HF have been previously studied in a cohort of 344 patients. In that prospective study, onset of AF was associated with clinical worsening of HF decrease in peak oxygen consumption and cardiac index and development of mitral and tricuspid regurgitation all of which translated to overall poorer prognosis. 24 In terms of hospital management, adherence to quality measures of the participating hospitals was relatively high with patients discharged, with all-or-none composite measure rate Ͼ85%. Nevertheless, small statistically significant differences in the hospital management among the study subgroups were identified. Patients in AF received less diagnostic and therapeutic interventions related to coronary artery disease, namely stress testing, coronary angiography, and percutaneous interventions during hospitalization. An interesting difference was seen in device implantations. Patients in AF received almost twice as many pacemakers and half as many defibrillators as patients in sinus rhythm. The higher incidence of pacemaker implantation could be explained by the higher age in AF patients as well as the higher use of atrioventricular nodal blocking and antiarrhythmic agents that may exacerbate sinus node dysfunction in patients with paroxysmal AF. 25 In-hospital treatment of patients with new-onset AF was also significantly different than both patients in sinus rhythm and preexisting AF. Despite their more benign clinical profile before admission they underwent significantly more invasive procedures than other patients. Another important observation is that even though patients with newly diagnosed AF underwent significantly more cardioversions, they did so only in 4.2% of cases. Although it is possible that cases admitted in AF spontaneously converted to sinus rhythm after management of HF, and such practice cannot be captured by our registry, this scenario could not fully explain the very small number of cardioversion attempts in AF patients. Another plausible explanation of low cardioversion rates is the belief that cardioversion success could be lower in setting of decompensated failure, and many clinicians may have elected to perform cardioversion at a later time.
The main finding of our analysis was the significant difference in all primary outcome measures between patients with sinus rhythm and AF. Patients in AF, despite having fewer comorbidities on presentation, had lengthier hospital course and were more likely to be discharged to a facility other than home. More importantly, mortality in patients with AF was significantly higher despite the fact that they had lower prevalence of previously described predictors of mor-tality including lower EF, higher BNP, abnormal troponins, and presence of renal dysfunction. In the outpatient setting, the importance of AF in HF population has been demonstrated in several studies. The importance of AF in patients with chronic systolic HF has been shown in the Studies of Left Ventricular Dysfunction (SOLVD) and Carvedilol or Metoprolol European Trial (COMET) trials. SOLVD found that AF was an independent predictor for all-cause mortality in 6500 patients with EF Յ35%, 10 whereas in a retrospective analysis of the COMET, AF was associated with increased unadjusted risk of death and HF hospitalization in 3029 with depressed EF. 14 However, after adjusting for covariates, AF was not found to independently predict mortality. Similarly, Middlekauff et al 7 showed that patients in AF and advanced HF had significantly worse 1-year survival than patients in sinus rhythm. The importance of AF in patients developing HF after acute myocardial infarction was shown in the Actual numbers are presented on first row of each categorical variable and percentages on the second. GWTG-HF indicates Get With The Guideline-Heart Failure; AF, atrial fibrillation; EF, ejection fraction; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor antagonist; DVT, deep venous thrombosis; ICD, implantable cardioverter defibrillator; HF, heart failure. *P comparison between sinus rhythm, preexisting AF, and new-onset AF. †P comparison between preexisting and new-onset AF. ‡Statistically significant differences.
Valsartan in Acute Myocardial Infarction (VALIANT) trial, where AF was associated with greater long-term morbidity and mortality in 14 703 patients. 15 The results of these studies are in contrast to smaller prior studies were AF was not associated with worse long-term outcome. More specifically, the Vasodilator Heart Failure Trial (V-HeFT) showed no difference in mortality in 1427 outpatients with mild to moderate HF. 8 Similarly, in 2 smaller studies, AF was not Figure 2 . Hospital outcomes stratified by atrial fibrillation (AF) groups. Patients in new-onset AF had lengthier hospital stay and higher hospital mortality than both patients with preexisting AF and patients in sinus rhythm. Patients in AF (new onset or preexisting) were more likely to be discharged to a facility other than home. associated with worse mortality in patients with advanced HF. 11, 12 In the Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) study, Pedersen et al 16 studied the association of AF with outcomes in 3587 patients admitted with decompensated HF. In this study, in-hospital mortality was similar between patients presenting in AF and sinus rhythm. 16 An interesting finding of our study is that the worse hospital outcomes were in patients with newly diagnosed AF. New-onset AF had been previously linked to long-term mortality in the outpatient setting. Ahmed et al 26 showed in a retrospective analysis of 944 hospitalized elderly patients with HF that new onset AF but not preexisting AF carried a significantly higher risk for 4 year all-cause mortality. Similar association between new-onset AF and mortality and absence of association between preexisting AF and mortality was reported in an analysis of COMET trial. 14 Whether this association between new-onset AF and mortality is causative or development of AF is simply a marker of advanced disease is unclear. In addition to the adverse hemodynamic consequences of AF, management of new-onset AF, including initiation of anticoagulation and antiarrhythmic agents, espe-cially in setting of HF, may be challenging and result in higher morbidity and mortality.
In our study, the associations between AF and outcomes in the adjusted analyses were similar for patients with preserved and low EF (EF Ն40% and Ͻ40%). One could have expected worse outcomes in patients with AF and preserved EF; however, our finding helps to reinforce the overall findings and shows the relationship between AF and outcomes applies irrespective of type of HF. Clear associations between AF and mortality in either hospitalized patients with preserved EF HF has not, to the best of our knowledge, been previously demonstrated.
Limitations
The retrospective nature of the analysis is an inherent limitation of the study. The registry is dependent on accuracy of data and the completeness of data abstraction from medical charts. Certain variables were not routinely collected or missing from the database. Limitation in some types of data also precluded the assessment of important variables such as evolution of rhythm during hospitalization. Therefore, we were unable to report the number of patients who although they presented in AF, subsequently converted spontaneously Variables included in adjustment: demographics: age (per 10 years), race (whites/blacks/Hispanic/others), and sex. Medical history (imputed to no): chronic obstructive pulmonary disease, stroke, depression, diabetes, renal failure, dyslipidemia, hypertension, peripheral vascular disease, smoking, ischemic etiology, and valve disease. Vitals (imputed with group-specific medians): heart rate (splines with knots at 75 and 105) and systolic blood pressure (per 5 mm Hg). Laboratories (not imputed): sodium (splines with knots at 35 and 40), hemoglobin (truncated at 12), creatinine (truncated at 1 and 3.5 mg/dL), and urea (per 5 units). Hospital (not imputed): region, academic status, and heart transplant capability.
to sinus rhythm and the number of patients who developed AF during the course of their hospital stay. In addition, we were not able to evaluate the association of restoration of sinus rhythm with hospital outcomes. It is possible that patients with asymptomatic chronic AF may have been included in the new-onset AF group. Determination of EF could have largely been affected by the underlying rhythm as well as rate and therefore the timing of echocardiogram could have also influenced differences in EF. Given the observational nature of the study, residual measured and unobserved variables may have confounded some or all of the findings. Because of the large number of patients in this study, some small differences might lead to statistical significance but lack clinical relevance. Postdischarge data, including mortality and readmissions, were not available and will require further study. There is also the possibility that the cohort derived from a voluntary registry may differ from hospitals not willing to participate, but prior research evaluating this hypothesis found participants in registries to have in-hospital mortality similar to that in nonparticipants. 27 
Conclusions
Among hospitals participating in GWTG-HF, AF is present in a third of patients who were hospitalized with HF. Patients in AF were older and more likely to have stroke and valvular heart disease. AF, particularly newly diagnosed, was independently associated with adverse in-hospital outcomes among patients hospitalized with HF, including a significantly higher mortality rate. This association appears to be present for both patients with reduced as well as preserved left ventricular EF. Whether AF or its related treatment is the mediator of these adverse outcomes or whether AF represents a marker of greater HF severity cannot be addressed by this analysis. Future studies addressing the importance of prompt restoration of sinus rhythm in patients in AF are important in better defining the optimal treatment of these patients.
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